Maxim Sysoev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maxim Sysoev has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Allan V. Kalueff
Institute of Translational Biomedicine, St. Petersburg State University, 199034 St. Petersburg, Russia
3 shared publications - Murilo Sander de Abreu
Graduate Program in Health Sciences, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil
3 shared publications Andrey D. Volgin
Scientific Research Institute of Physiology and Basic Medicine, Novosibirsk, Russia
2 shared publicationsCai Song
Research Institute of Marine Drugs and Nutrition, Guangdong Ocean University, Zhanjiang, Guangdong, China
2 shared publicationsErik T. Alpyshov
School of Pharmacy, Southwest University, Chongqing, China
2 shared publications- Konstantin A. Demin
Institute of Translational Biomedicine, St. Petersburg State University, 199034 St. Petersburg, Russia
2 shared publications
Latest Publications
- 1 May 2019
- Published by Elsevier in Brain Research Bulletin
- Vol. 148, 55-62
Modeling gut-brain interactions in zebrafish
- 1 May 2019
- Published by Elsevier in Brain Research Bulletin
- Vol. 148, 55-62
Modeling gut-brain interactions in zebrafish
- 1 May 2019
- Published by Elsevier in Aquatic Toxicology
- Vol. 210, 44-55
The role of intraspecies variation in fish neurobehavioral and neuropharmacological phenotypes in aquatic models
- 1 May 2019
- Published by Elsevier in Aquatic Toxicology
- Vol. 210, 44-55
The role of intraspecies variation in fish neurobehavioral and neuropharmacological phenotypes in aquatic models
- 22 February 2019
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 14 (4) , 365-378
Animal models of major depressive disorder and the implications for drug discovery and development
Introduction: Depression is a highly debilitating psychiatric disorder that affects the global population and causes severe disabilities and suicide. Depression pathogenesis remains poorly understood, and the disorder is often treatment-resistant and recurrent, necessitating the development of novel therapies, models and concepts in this field. Areas covered: Animal models are indispensable for translational biological psychiatry, and markedly advance the study of depression. Novel approaches continuously emerge that may help untangle the disorder heterogeneity and unclear categories of disease classification systems. Some of these approaches include widening the spectrum of model species used for translational research, using a broader range of test paradigms, exploring new pathogenic pathways and biomarkers, and focusing more closely on processes beyond neural cells (e.g. glial, inflammatory and metabolic deficits). Expert opinion: Dividing the core symptoms into easily translatable, evolutionarily conserved phenotypes is an effective way to reevaluate current depression modeling. Conceptually novel approaches based on the endophenotype paradigm, cross-species trait genetics and ‘domain interplay concept’, as well as using a wider spectrum of model organisms and target systems will enhance experimental modeling of depression and antidepressant drug discovery.
- 22 February 2019
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 14 (4) , 365-378
Animal models of major depressive disorder and the implications for drug discovery and development
Introduction: Depression is a highly debilitating psychiatric disorder that affects the global population and causes severe disabilities and suicide. Depression pathogenesis remains poorly understood, and the disorder is often treatment-resistant and recurrent, necessitating the development of novel therapies, models and concepts in this field. Areas covered: Animal models are indispensable for translational biological psychiatry, and markedly advance the study of depression. Novel approaches continuously emerge that may help untangle the disorder heterogeneity and unclear categories of disease classification systems. Some of these approaches include widening the spectrum of model species used for translational research, using a broader range of test paradigms, exploring new pathogenic pathways and biomarkers, and focusing more closely on processes beyond neural cells (e.g. glial, inflammatory and metabolic deficits). Expert opinion: Dividing the core symptoms into easily translatable, evolutionarily conserved phenotypes is an effective way to reevaluate current depression modeling. Conceptually novel approaches based on the endophenotype paradigm, cross-species trait genetics and ‘domain interplay concept’, as well as using a wider spectrum of model organisms and target systems will enhance experimental modeling of depression and antidepressant drug discovery.